Abstract Search

ea0090p416 | Pituitary and Neuroendocrinology | ECE2023

Treatment, complications and mortality of Cushing’s Disease: twenty-year report from a referral Centre

Mondin Alessandro , Ceccato Filippo , Voltan Giacomo , Mazzeo Pierluigi , Tizianel Irene , Scaroni Carla , Barbot Mattia

Context: Cushings disease (CD) is rare condition burdened by several systemic complications that in turn increase mortality. The main goal of CD treatment is to promptly reduce cortisol excess, but whether remission can revert cortisol-related complications and guarantee a normal life expectancy remains debated. Aim: To assess the prevalence of cortisol-related complications and mortality in a large monocentric cohort of CD patients followed at our...

2 shares

ea0099ep196 | Adrenal and Cardiovascular Endocrinology | ECE2024

Metabolic impact of dual-release hydrocortisone in patients with congenital adrenal syndrome: a retrospective study

Mazzeo Pierluigi , Ceccato Filippo , Voltan Giacomo , Tizianel Irene , Mondin Alessandro , Lazzara Martina , Bavaresco Alessandro , Barbot Mattia

Background: Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder characterized by impaired cortisol secretion and androgen excess. The mainstay of CAH treatment is glucocorticoid (GC) replacement, necessary to avoid adrenal crisis and manage androgen excess. The delicate balance between GC under/overtreatment is crucial to prevent metabolic and cardiovascular complications. Dual-release hydrocortisone (Plenadren®) is once-daily modified-release formulat...

1 shares

ea0099ep1229 | Late Breaking | ECE2024

Steroidogenesis inhibitors in mild/subclinical cushing’s syndrome: results from a retrospective cohort of patients

Bavaresco Alessandro , Ceccato Filippo , Mazzeo Pierluigi , Lazzara Martina , Voltan Giacomo , Tizianel Irene , Mondin Alessandro , Barbot Mattia

Cushings syndrome (CS) is a severe disease associated with elevated morbidity and mortality rates, up to four times higher than those of general population. Whether the positive effects of cortisol-lowering medications is widely documented in overt CS cases, its impact on mild or subclinical CS remains unclear since limited clinical investigations have been performed in patients with subclinical hypercortisolism. In this study, we retrospectively analysed clinical data f...

1 shares

ea0081p271 | Adrenal and Cardiovascular Endocrinology | ECE2022

The accuracy of adjusted unconventional indices for the assessment of selectivity and lateralization of adrenal vein sampling in the subtype diagnosis of primary aldosteronism

Bollati Martina , Parasiliti-Caprino Mirko , Bioletto Fabio , Ceccato Filippo , Lopez Chiara , Di Carlo Maria Chiara , Voltan Giacomo , Rossato Denis , Giraudo Giuseppe , Scaroni Carla , Ghigo Ezio , Maccario Mauro

Objective: This study aimed to evaluate the performance of simple and clinical/imaging-corrected unconventional indices in predicting the selectivity of adrenal vein sampling (AVS) and the lateralization of aldosterone hypersecretion in patients with primary aldosteronism (PA).Methods: Data of all consecutive patients with a proven diagnosis of PA who underwent AVS for subtype differentiation in two Italian referral centers were analyzed retrospectively....

0 shares

ea0090p811 | Late-Breaking | ECE2023

Comparison of Metyrapone, OSilodrostat and KEToconazolE in the short-term thERapy of endogenous Cushing’s syndrome: preliminary results of the MOSKETEER study

Detomas Mario , Simeoli Chiara , Ceccato Filippo , Aulinas Maso Ana , Dolce Pasquale , Rubinstein German , Antonini Simone , Stelmachowska-Banaś Maria , Minnetti Marianna , Corsello Andrea , Dischinger Ulrich , Di Paola Nicola , Voltan Giacomo , Santos Vives Alicia , Braun Leah , Mazzarella Alessandro , DEUTSCHBEIN Timo , Lania Andrea , Isidori Andrea , Reincke Martin , Carla Scaroni , M Webb Susan , Pivonello Rosario , Fassnacht Martin , Altieri Barbara

Background: Steroid synthesis inhibitors, like metyrapone, osilodrostat, and ketoconazole are used as second-line treatment in all types of endogenous Cushings syndrome (CS). However, a direct comparison of these three drugs is missing. This study aimed to compare these drugs in the short-term therapy of CS.Design: Retrospective multicenter study involving 15 European centers.Methods: Patients with CS treated with metyrapone,...

5 shares

ea0093oc14 | Oral communication 2: Neuroendocrinology | EYES2023

Comparison of metyrapone, osilodrostat and ketoconazole in the short-term therapy of endogenous Cushing’s syndrome: Preliminary results of the Mosketeer study

Detomas Mario , Simeoli Chiara , Di Paola Nicola , Mazzarella Alessandro , Pivonello Rosario , Ceccato Filippo , Voltan Giacomo , Scaroni Carla , Aulinas Anna , Santos Alicia , Webb Susan , Rubinstein German , Braun Leah , Reincke Martin , Dolce Pasquale , Antonini Simone , Lania Andrea , Stelmachowska-Banaś Maria , Cylke-Falkowska Karolina , Minnetti Marianna , Isidori Andrea M. , Corsello Andrea , Gilis-Januszewska Aleksandra , Minasyjan Mari , Sambula Lana , Kastelan Darko , Deutschbein Timo , Haberbosch Linus , Dischinger Ulrich , Fassnacht Martin , Altieri Barbara

Background: Steroid synthesis inhibitors, like metyrapone, osilodrostat, and ketoconazole are used as second-line treatment in all types of endogenous Cushings syndrome (CS). However, a direct comparison of these three drugs is missing. This study aimed to compare these drugs in the short-term therapy of CS.Design: Retrospective multicenter study involving 16 centers worldwide.Methods: Patients with CS treated with metyrapone...

2 shares

ea0099rc13.3 | Rapid Communications 13: Late Breaking | ECE2024

Comparison of metyrapone, osilodrostat and ketoconazole in the therapy of endogenous Cushing’s syndrome: The MOSKETEER study

Detomas Mario , Ceccato Filippo , Simeoli Chiara , Dolce Pasquale , Aulinas Maso Ana , Gilis-Januszewska Aleksandra , Parasiliti Caprino Mirko , Bassiony Mohamed , Stelmachowska-Banaś Maria , Ferrante Emanuele , Pittaway James , Rubinstein German , Hanzu Felicia A , Pmglisi Soraya , Corsello Andrea , Antonini Simone , Sambula Lana , Minnetti Marianna , Haberbosch Linus , Deutschbein Timo , Dischinger Ulrich , Voltan Giacomo , Di Paola Nicola , Santos Vives Alicia , Minasyan Mari , Giordano Roberta , Fell Vanessa , Cylke-Falkowska Karolina , Mangone Alessandra , Plowman Christina , Vega Arturo , Braun Leah , Mazzarella Alessandro , Locantore Pietro , Faggiano Antongiulio , Terzolo Massimo , Lania Andrea , Kastelan Darko , Isidori Andrea , Reincke Martin , Bancos Irina , Arvat Emanuela , Webb Susan M , Carla Scaroni , Pivonello Rosario , Fassnacht Martin , Altieri Barbara

Background: Metyrapone, osilodrostat, and ketoconazole are steroidogenesis inhibitors used as second-line treatment in endogenous Cushings syndrome (CS). However, a direct comparison of these three drmgs is missing.Objective: To compare the efficacy of the three drmgs after short-term therapy (≤12 weeks) for CS.Methods: Multicenter, real-life retrospective study involving 20 centers worldwide. Patients with CS treated w...